Trial
NCT04034446
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
Early Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Juventas Cell Therapy Ltd.
Condition
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Intervention
CD19-CD22 CAR-T cells
Why stopped
Due to adjustments in the company's strategy, the research and development of this project has been terminated.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-03